Lourdes Riquelme, Author at Labiotech.eu

About

Spanish Biotechnologist with a MS in Genetics from Universidad Autonoma of Barcelona. My interests go from science to fashion and anything in between.

Articles by Lourdes Riquelme

News and Trends 22 Apr 2015

Synthetic sea anemone’s peptide to cure Autoimmune Diseases

Kineta and researchers from the University of Groningen, Netherlands, announced new data from a study that showed dalazatide (formerly ShK-186) is effective in immunomodulating the cells causing inflammation and damage of small blood vessels in various organs in samples from patients with Granulomatosis with Polyangiitis (GPA). The data were presented at the 17th International ANCA […]

April 22, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 22 Apr 2015

Erytech Strengthens its Intellectual Property Position in the US

Erytech strengthed its intellectual property portfolio in the United States with the granting of a new patent and the further extension of the patent term of its core process patent. The French biopharmaceutical company develops innovative ‘tumor starvation’ treatments for acute leukemia and other oncology indications with unmet medical needs. The patent entitled “Medicament for […]

April 22, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 21 Apr 2015

GATC backs Molecular Health’s tumour profiling system

GATC Biotech has signed a commercial agreement with Molecular Health to market and support Molecular Health’s state-of-the-art system for tumour profiling. Under this agreement, GATC Biotech will make the company’s analytical software, TreatmentMAP, available to patients worldwide. Every cancer is unique, which is why cancer patients respond differently to cancer treatments. Scientific discoveries and technological […]

April 21, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 21 Apr 2015

Annette Clancy joins Lysogene’s Board of Directors

Annette Clancy has been appointed Chair of the Board of Directors of Lysogene, a leading clinical-stage company focused on gene therapy to treat Central Nervous System (CNS) disorders. Ms. Karen Aiach, Founder and CEO of Lysogene, who has led Lysogene in translating its rAAVrh10 lead product for Sanfilippo from bench to bedside in an unprecedented fashion, stated: […]

April 21, 2015 - 2 minutesmins - By Lourdes Riquelme

TEVA Eagle Pharmaceuticals leukemia bendamustine

News and Trends 17 Apr 2015

Teva took the first step to get the approval of its new leukemia treatment

FDA accepted Teva Pharma’s New Drug Application (NDA) for a liquid bendamustine hydrochloride (HCl) rapid infusion product. The drug, developed with Eagle Pharmaceuticals is now waiting for the Prescription Drug User Fee Act (PDUFA), which is expected for December 2015. In the meantime, the Israeli company remains unstoppable after a great begining of the month on […]

April 17, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 17 Apr 2015

Merck Serono bets on Oncology with the appointment of Dr. Alise Reicin

Merck Serono appointed Dr. Alise Reicin as Senior Vice President, Head of Global Clinical Development. The appointment is yet another example of Merck’s clear interest in oncology and immunology, two fields in which Dr. Reicin expertised. Dr. Reicin will also bring extensive research and early/late clinical development expertise to Merck Serono. In her role as […]

April 17, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 16 Apr 2015

The first-in-human Phase I trial for a treatment against glaucoma core

Isarna Therapeutics has initiated Phase I clinical trial with ISTH0036, an antisense oligonucleotide selectively targeting transforming growth factor beta (TGF-ß2) to treat advanced glaucoma. This first-in-human Phase I trial, conducted at the University Hospitals of Mainz and Tuebingen, Germany, is designed to evaluate the safety and long-term tolerability of ISTH0036 in patients with advanced glaucoma […]

April 16, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 16 Apr 2015

Wilson Therapeutics on its way to cure Wilson disease

Wilson Therapeutics has closed a €37.4M Series B financing to advance its late-stage development program for Wilson’s disease. The company will present its ongoing Phase II trial of WTX101-201, the company’s treatment for this disease, at the upcoming 50th International Liver Congress 2015. Approximately 1 in 15000 people worldwide have Wilson Disease, a rare genetic disorder that prevents the […]

April 16, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 15 Apr 2015

Synthetic bio: one single Grapefruit to produce one Million liters of Juice

The Austrian Centre of Industrial Biotechnology (acib), using synthetic biology technology, developed a new method to produce Nootkatone, an expensive grapefruit aroma. The biotechnological process uses cheap sugar as substrate for a “turbo-yeast”. The extremely expensive substance is used in soft drinks, pharmaceutical products or even as an insect repellent, and it is found only […]

April 15, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 15 Apr 2015

Heart Metabolics bargain with the FDA for a single Phase III

Heart Metabolics received an agreement letter from the FDA related to the company’s proposed phase III trial Special Protocol Assessment (SPA) request. The FDA has agreed to a single, randomized, pivotal Phase III trial of 350 patients evaluating perhexiline for the treatment of moderate-to-severe hypertrophic cardiomyopathy (HCM). The company, focused on the development of drugs […]

April 15, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 15 Apr 2015

AstraZeneca avoided a public crisis of its marketed diabetes treatment

Last week, FDA expressed its concerns about AstraZeneca’s treatment for type 2 diabetes, Onglyza. According to Reuters, FDA found “significant or near significant” increase of death risk. However, the agency also admits that the cause of death is multifactorial and could not be directly related to AstraZeneca’s treatment. The drug was developed as a result […]

April 15, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 14 Apr 2015

Novacyt raised €2.2M to accelerate its technology’s launching in China

Novacyt announced a private equity placement financing of €2.2M that will be used to accelerate the launch of NOVAprep into China with its distribution partner Leica Biosystems, now scheduled for Q2 2015. This follows the successful financing of €3.1M in December 2014. This latest financing attracted support from current investors including Alto Invest, and a […]

April 14, 2015 - 2 minutesmins - By Lourdes Riquelme

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Lourdes Riquelme

About

Articles by Lourdes Riquelme

Synthetic sea anemone’s peptide to cure Autoimmune Diseases

Erytech Strengthens its Intellectual Property Position in the US

GATC backs Molecular Health’s tumour profiling system

Annette Clancy joins Lysogene’s Board of Directors

Teva took the first step to get the approval of its new leukemia treatment

Merck Serono bets on Oncology with the appointment of Dr. Alise Reicin

The first-in-human Phase I trial for a treatment against glaucoma core

Wilson Therapeutics on its way to cure Wilson disease

Synthetic bio: one single Grapefruit to produce one Million liters of Juice

Heart Metabolics bargain with the FDA for a single Phase III

AstraZeneca avoided a public crisis of its marketed diabetes treatment

Novacyt raised €2.2M to accelerate its technology’s launching in China

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

About

Articles by Lourdes Riquelme

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!